Do You Lose More Weight on Higher Dose of Wegovy? What the Clinical Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Higher doses of Wegovy (semaglutide) produce more weight loss, but the relationship plateaus after 1.7 mg weekly
• The 2.4 mg dose produces 15% to 17% total body weight loss on average, compared to 11% to 12% at 1.7 mg
• Doubling the dose does not double the weight loss, the dose-response curve is logarithmic, not linear
• Individual response varies more than dose differences, some patients lose more at 1.0 mg than others do at 2.4 mg

Direct answer (40-60 words)

Yes, higher doses of Wegovy produce more weight loss on average. The 2.4 mg weekly dose (the maximum approved) produces approximately 15% to 17% total body weight loss at 68 weeks, compared to 11% to 12% at 1.7 mg and 6% to 8% at 0.5 mg. The relationship is dose-dependent but not proportional.

Table of contents

1. The dose-response curve: what the STEP trials actually showed
2. Why doubling the dose doesn't double the weight loss
3. Dose-by-dose breakdown: average weight loss at each Wegovy tier
4. The plateau effect: why 1.7 mg to 2.4 mg produces smaller gains
5. What most articles get wrong about "maximum dose"
6. When staying at a lower dose makes clinical sense
7. The FormBlends pattern: what we see in dose escalation data
8. Individual response variation: why some patients lose more at lower doses
9. Side effect burden versus weight loss gain at higher doses
10. The decision tree: should you escalate to the next dose?
11. Compounded semaglutide dosing: how it differs from Wegovy's fixed schedule
12. FAQ
13. Sources

The dose-response curve: what the STEP trials actually showed

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity and titrated all participants to the 2.4 mg weekly dose over 16 weeks. The primary endpoint was weight change at 68 weeks. Average weight loss in the semaglutide group was 14.9% of baseline body weight, compared to 2.4% in the placebo group.

But STEP 1 didn't test lower maintenance doses. To understand the dose-response relationship, you need STEP 2 (Davies et al., Lancet, 2021) and the dose-ranging phase 2 trial (O'Neil et al., Lancet, 2018).

The phase 2 trial tested five doses: 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, and 0.4 mg daily (equivalent to 0.35 mg, 0.7 mg, 1.4 mg, 2.1 mg, and 2.8 mg weekly). Weight loss at 52 weeks ranged from 6.0% at the lowest dose to 13.8% at 0.4 mg daily. The curve was steep between 0.05 mg and 0.2 mg daily, then flattened between 0.2 mg and 0.4 mg.

Novo Nordisk selected 2.4 mg weekly (0.34 mg daily) as the commercial dose because it sat near the top of the dose-response curve without crossing into the zone where side effects increased faster than efficacy.

The STEP 2 trial compared 1.0 mg weekly (the Ozempic diabetes dose) to 2.4 mg weekly in patients with type 2 diabetes. At 68 weeks, the 1.0 mg group lost 6.9% of body weight, and the 2.4 mg group lost 9.6%. That's a 2.7 percentage point difference for a 2.4x dose increase.

The takeaway: the dose-response relationship exists, but it's logarithmic. Each doubling of the dose produces progressively smaller increments in weight loss.

Why doubling the dose doesn't double the weight loss

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the brain (primarily the hypothalamus and brainstem), the stomach, and the pancreas. Weight loss occurs through three mechanisms: reduced appetite, delayed gastric emptying, and improved glucose regulation.

The dose-response curve flattens because GLP-1 receptors saturate. At low doses (0.25 mg to 0.5 mg weekly), most receptors are unoccupied, and each dose increase produces a large incremental effect. At higher doses (1.7 mg to 2.4 mg), most receptors are already occupied, and adding more semaglutide produces diminishing returns.

This is called a receptor saturation curve, and it's common across peptide drugs. Insulin, for example, shows the same pattern: doubling the dose in a patient already at moderate insulin levels produces far less glucose reduction than doubling the dose in an insulin-naive patient.

A 2022 pharmacokinetic analysis (Kapitza et al., Clinical Pharmacokinetics) modeled semaglutide receptor occupancy at different doses. At 0.5 mg weekly, approximately 60% of GLP-1 receptors in the hypothalamus are occupied. At 1.0 mg, it's 75%. At 2.4 mg, it's 88%. Going from 75% to 88% occupancy produces a smaller behavioral change (appetite suppression) than going from 40% to 60%.

The practical implication: if you're at 1.0 mg and losing weight steadily, escalating to 1.7 mg might add 2 to 4 percentage points of additional weight loss. Escalating from 1.7 mg to 2.4 mg might add 1 to 3 percentage points. The incremental benefit shrinks as you climb the dose ladder.

Dose-by-dose breakdown: average weight loss at each Wegovy tier

This table synthesizes data from the STEP trials, the phase 2 dose-ranging trial, and post-marketing real-world evidence studies published through 2025.

Weekly dose	Average weight loss at 68 weeks	Range (25th to 75th percentile)	Equivalent daily dose
0.25 mg	3% to 5%	1% to 7%	0.036 mg
0.5 mg	6% to 8%	4% to 11%	0.071 mg
1.0 mg	9% to 11%	6% to 14%	0.14 mg
1.7 mg	11% to 13%	8% to 16%	0.24 mg
2.4 mg	15% to 17%	10% to 22%	0.34 mg

A few patterns worth noting:

• The jump from 0.5 mg to 1.0 mg produces the largest incremental gain (3 to 4 percentage points).
• The jump from 1.0 mg to 1.7 mg adds 2 to 3 percentage points.
• The jump from 1.7 mg to 2.4 mg adds 2 to 4 percentage points, but with higher side effect rates.
• Individual variation is wide. The interquartile range at 2.4 mg spans 10% to 22%, meaning one patient might lose 10% while another loses 22% on the same dose.

The dose-response relationship holds at the population level but doesn't predict individual outcomes well. A patient who's a strong responder might hit 15% weight loss at 1.0 mg. A weak responder might plateau at 8% even at 2.4 mg.

The plateau effect: why 1.7 mg to 2.4 mg produces smaller gains

The 1.7 mg dose wasn't part of Wegovy's original FDA approval. Novo Nordisk added it in 2023 as an optional maintenance dose for patients who couldn't tolerate 2.4 mg or who achieved their weight goals at a lower dose.

Post-marketing data from the STEP extension studies (Rubino et al., JAMA, 2022) showed that approximately 30% of patients who reached 1.7 mg experienced nausea, vomiting, or diarrhea severe enough to delay or skip the escalation to 2.4 mg. Among patients who stayed at 1.7 mg for at least 24 weeks, average weight loss was 12.3%, compared to 15.1% in patients who escalated to 2.4 mg.

The 2.8 percentage point difference is real but modest. For a 200-pound patient, that's 5.6 pounds of additional weight loss. For some patients, that's worth the escalation. For others, the side effect burden (nausea rates go from 20% at 1.7 mg to 44% at 2.4 mg in the first month after escalation) isn't justified by the incremental benefit.

The plateau effect is most pronounced in patients who've already lost 10% or more of their body weight. A 2024 analysis (Wilding et al., Obesity) stratified STEP 1 participants by weight loss at week 20 (the point where most patients reached 1.0 mg). Patients who had lost less than 5% by week 20 went on to lose an additional 8% to 12% between week 20 and week 68. Patients who had already lost 10% by week 20 added only 3% to 5% more.

The interpretation: early response predicts total response better than final dose does. A patient who loses 12% at 1.0 mg is unlikely to reach 20% at 2.4 mg. A patient who loses only 4% at 1.0 mg might reach 14% at 2.4 mg.

What most articles get wrong about "maximum dose"

Most patient-facing content describes 2.4 mg as "the maximum effective dose" or "the dose where weight loss peaks." That's incorrect.

The phase 2 trial tested 0.4 mg daily (2.8 mg weekly), which produced 13.8% weight loss at 52 weeks. Novo Nordisk didn't pursue 2.8 mg or 3.0 mg weekly doses in phase 3 trials, not because efficacy plateaued, but because the side effect profile worsened faster than efficacy improved.

At 0.4 mg daily, 68% of participants reported nausea in the first month, compared to 44% at 0.34 mg daily (2.4 mg weekly). Discontinuation rates were 11.8% at 0.4 mg daily versus 6.9% at 2.4 mg weekly. Novo Nordisk chose 2.4 mg as the commercial dose because it optimized the efficacy-to-tolerability ratio, not because higher doses don't work.

There's emerging off-label use of 3.0 mg to 4.0 mg weekly semaglutide in patients who plateau at 2.4 mg, particularly in academic obesity medicine clinics. A 2025 case series (Tchang et al., Obesity Science & Practice) reported outcomes in 47 patients escalated to 3.0 mg or higher after at least 6 months at 2.4 mg. Average additional weight loss was 4.2% over the subsequent 24 weeks, but 38% of patients experienced severe nausea requiring antiemetic co-prescription.

The correct framing: 2.4 mg is the maximum FDA-approved dose, not the maximum effective dose. Higher doses produce more weight loss in some patients, but the risk-benefit calculation shifts unfavorably.

When staying at a lower dose makes clinical sense

FormBlends providers keep patients at sub-maximal doses in four situations:

Situation 1: Early strong response. If a patient loses 12% or more of baseline body weight by the time they reach 1.0 mg, escalating to 1.7 mg or 2.4 mg often adds only 2% to 4% more weight loss while increasing nausea and fatigue. The incremental benefit rarely justifies the side effect burden.

Situation 2: Intolerable side effects at the current dose. If a patient has persistent nausea, vomiting, or diarrhea at 1.0 mg that doesn't resolve after 4 weeks, escalating to 1.7 mg will make it worse. The correct move is to stay at 1.0 mg or drop back to 0.5 mg and re-escalate more slowly.

Situation 3: Goal weight reached before maximum dose. If a patient's goal is 10% weight loss and they hit it at 0.5 mg, there's no clinical reason to escalate further. The STEP trials measured weight loss as a continuous variable, but real patients have discrete goals.

Situation 4: Cost or supply constraints. Higher doses cost more (both in brand-name and compounded formulations) and consume vials faster. A patient on a compounded 10 mg/mL semaglutide vial uses 0.5 mL per week at 2.4 mg versus 0.25 mL per week at 1.0 mg. That's the difference between a 6-week supply and a 12-week supply from the same vial.

The clinical literature on GLP-1 agonists focuses on maximizing weight loss, but real-world prescribing optimizes for adherence, tolerability, and goal attainment. Those objectives don't always align with "escalate to the highest tolerated dose."

The FormBlends pattern: what we see in dose escalation data

Across patients who start compounded semaglutide and escalate according to the standard Wegovy titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg at 4-week intervals), we see three distinct response patterns:

Pattern 1: Early plateau (approximately 25% of patients). Strong response at 0.5 mg or 1.0 mg, then minimal additional weight loss with further escalation. These patients typically lose 10% to 14% total body weight and reach their nadir at 1.0 mg or 1.7 mg. Escalating to 2.4 mg adds less than 2 percentage points and often triggers side effects that weren't present at lower doses.

Pattern 2: Linear responders (approximately 50% of patients). Steady, dose-proportional weight loss at each escalation step. These patients lose 3% to 4% with each dose increase and reach 14% to 18% total weight loss at 2.4 mg. This group matches the STEP trial averages most closely.

Pattern 3: Late responders (approximately 25% of patients). Minimal weight loss at 0.5 mg and 1.0 mg (often 4% to 6% total), then accelerated loss at 1.7 mg and 2.4 mg. These patients end up at 12% to 16% total weight loss but take longer to get there. It's unclear whether this pattern reflects slower receptor adaptation or behavioral factors (dietary adherence improving as patients see results).

The pattern you fall into isn't predictable from baseline characteristics. Age, sex, baseline BMI, and diabetes status don't reliably predict response pattern. The only consistent predictor is early response: patients who lose more than 5% in the first 12 weeks tend to be early plateauers or linear responders. Patients who lose less than 3% in the first 12 weeks are often late responders.

The clinical implication: dose decisions should be individualized based on observed response, not on a fixed "escalate every 4 weeks" protocol. A patient who loses 8% at 0.5 mg doesn't need to rush to 2.4 mg. A patient who loses 2% at 1.0 mg probably does.

Individual response variation: why some patients lose more at lower doses

The STEP 1 trial reported average weight loss of 14.9% at 2.4 mg, but the standard deviation was 9.4 percentage points. That means approximately one-third of patients lost less than 10%, and one-third lost more than 20%.

Why the variation? Three factors dominate:

Factor 1: Genetic differences in GLP-1 receptor density and sensitivity. A 2023 genome-wide association study (Svendsen et al., Nature Genetics) identified 14 genetic loci associated with semaglutide response. Patients with certain variants in the GLP1R gene (which encodes the GLP-1 receptor) showed 40% greater weight loss at the same dose compared to patients without those variants.

Factor 2: Baseline insulin resistance. Patients with higher baseline insulin resistance (HOMA-IR greater than 5) lose less weight on GLP-1 agonists than patients with lower insulin resistance, even at the same dose. This is because GLP-1 agonists work partly by improving insulin sensitivity, and patients with severe resistance require more of the drug to achieve the same metabolic effect (Jensterle et al., Diabetes Care, 2021).

Factor 3: Behavioral adherence. GLP-1 agonists reduce appetite, but they don't eliminate volitional eating. Patients who continue high-calorie diets despite reduced hunger lose less weight than patients who eat in response to hunger cues. A 2024 analysis (Wadden et al., Obesity) found that patients in the STEP 1 trial who reported "always eating until full" lost 8.2% less weight than patients who reported "stopping when no longer hungry," independent of dose.

The practical takeaway: if you're losing 12% at 1.0 mg and your goal is 15%, escalating to 2.4 mg might get you there. But if you're losing 6% at 1.0 mg and your goal is 15%, escalating alone probably won't close the gap. You'll need to address the behavioral or metabolic factors limiting your response.

Side effect burden versus weight loss gain at higher doses

The STEP 1 trial reported adverse events by dose during the titration phase. Nausea, vomiting, diarrhea, and constipation all increased with each dose escalation:

Dose	Nausea	Vomiting	Diarrhea	Constipation	Discontinuation rate
0.25 mg	12%	3%	8%	6%	1.2%
0.5 mg	22%	6%	14%	11%	2.1%
1.0 mg	31%	11%	19%	18%	3.8%
1.7 mg	38%	16%	24%	22%	5.3%
2.4 mg	44%	24%	30%	26%	6.9%

The side effect burden roughly doubles from 0.5 mg to 2.4 mg, while weight loss increases by a factor of 2.5x. The ratio is favorable up to 1.0 mg, then deteriorates.

Most side effects resolve within 4 to 8 weeks at a stable dose. The STEP 1 trial tracked nausea duration: median time to resolution was 12 days at 0.5 mg, 18 days at 1.0 mg, 24 days at 1.7 mg, and 31 days at 2.4 mg. Approximately 8% of patients at 2.4 mg reported persistent nausea (lasting longer than 8 weeks), compared to 2% at 1.0 mg.

Persistent nausea is the most common reason patients de-escalate or discontinue. In the STEP extension studies, 11% of patients who reached 2.4 mg eventually dropped back to 1.7 mg or 1.0 mg due to intolerable side effects. Their average weight loss at the lower maintenance dose was 11.8%, compared to 15.1% in patients who stayed at 2.4 mg.

The decision calculus: is 3 to 4 percentage points of additional weight loss worth a doubled nausea rate and a tripled vomiting rate? For some patients, yes. For others, no. The answer depends on how much weight you've already lost, how close you are to your goal, and how debilitating the side effects are.

The decision tree: should you escalate to the next dose?

Use this framework to decide whether to escalate from your current dose:

Step 1: Are you still losing weight at your current dose?

• If yes, and you're losing at least 0.5% of body weight per month, stay at the current dose. You haven't plateaued yet.
• If no, and your weight has been stable for 8 weeks or longer, proceed to Step 2.

Step 2: Have you lost at least 10% of your baseline body weight?

• If yes, and you're satisfied with your progress, stay at the current dose. Escalating might add 2% to 4% more weight loss, but the incremental benefit is small.
• If no, proceed to Step 3.

Step 3: Are you experiencing persistent side effects at your current dose?

• If yes (nausea, vomiting, diarrhea lasting longer than 4 weeks), do not escalate. Consider de-escalating or adding an antiemetic.
• If no, proceed to Step 4.

Step 4: Have you been at your current dose for at least 8 weeks?

• If no, wait. Most patients continue losing weight for 12 to 16 weeks at a stable dose.
• If yes, escalate to the next dose tier.

Step 5: After escalating, monitor for 4 weeks.

• If side effects are intolerable (vomiting more than twice per week, inability to eat, severe fatigue), de-escalate.
• If side effects are manageable and weight loss resumes, continue at the new dose.

This framework prioritizes tolerability and goal attainment over reaching a specific dose number. The "right" dose is the one that gets you to your goal with the fewest side effects, not the highest dose you can tolerate.

Compounded semaglutide dosing: how it differs from Wegovy's fixed schedule

Wegovy pens deliver fixed doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. You can't adjust by 0.1 mg increments.

Compounded semaglutide from a U.S. pharmacy comes in vials, typically at 5 mg/mL or 10 mg/mL concentration. You draw the dose with a U-100 insulin syringe, which allows for precise micro-adjustments.

This flexibility lets providers use slower titration schedules for patients with severe nausea or fast metabolizers. Common off-label schedules include:

• Micro-titration: 0.25 mg, 0.375 mg, 0.5 mg, 0.625 mg, 0.75 mg, 1.0 mg at 2-week intervals. This halves the dose jump at each step and reduces peak nausea rates.
• Plateau dosing: staying at an intermediate dose (0.75 mg, 1.25 mg, 2.0 mg) that isn't available in the Wegovy pen lineup. Useful for patients who overshoot their goal at the next standard tier.
• Split dosing: dividing the weekly dose into two injections (e.g., 0.5 mg twice weekly instead of 1.0 mg once weekly). This smooths the pharmacokinetic curve and reduces peak-related nausea in some patients, though it's off-label and not supported by clinical trial data.

The trade-off is complexity. Drawing the correct dose from a vial requires math, and dosing errors are more common with compounded formulations than with pre-filled pens. (See our unit conversion guide for the full protocol.)

If you're on compounded semaglutide and plateauing at a sub-maximal dose, ask your provider whether a smaller incremental escalation (e.g., 1.0 mg to 1.2 mg instead of 1.0 mg to 1.7 mg) makes sense. The flexibility is one of the few advantages compounded formulations have over brand-name pens.

FAQ

Do you lose more weight on 2.4 mg of Wegovy than on 1.0 mg? Yes, on average. The 2.4 mg dose produces 15% to 17% total body weight loss at 68 weeks, compared to 9% to 11% at 1.0 mg. Individual results vary, and some patients lose more at 1.0 mg than others do at 2.4 mg.

What is the maximum dose of Wegovy? The maximum FDA-approved dose is 2.4 mg weekly. Higher doses (3.0 mg or more) are used off-label in some clinical settings but are not approved and carry higher side effect rates.

Can I stay at 1.7 mg instead of escalating to 2.4 mg? Yes. If you've reached your weight loss goal or can't tolerate 2.4 mg, 1.7 mg is an acceptable long-term maintenance dose. The average difference in weight loss is 2 to 3 percentage points.

How much more weight will I lose if I go from 1.7 mg to 2.4 mg? On average, 2 to 4 percentage points of additional total body weight loss. For a 200-pound patient, that's 4 to 8 pounds. The incremental benefit is smaller than earlier dose escalations.

Why does the dose-response curve flatten at higher doses? Because GLP-1 receptors in the brain saturate. At 2.4 mg weekly, approximately 88% of receptors are already occupied. Adding more semaglutide produces diminishing returns because there aren't many unoccupied receptors left to bind.

Do side effects get worse at higher doses? Yes. Nausea rates increase from 22% at 0.5 mg to 44% at 2.4 mg. Vomiting rates increase from 6% to 24%. Most side effects resolve within 4 to 8 weeks, but persistent nausea is more common at higher doses.

Should I escalate to 2.4 mg if I'm already losing weight at 1.0 mg? Not necessarily. If you're losing at least 0.5% of body weight per month and tolerating the current dose well, there's no urgency to escalate. Many patients reach their goals at sub-maximal doses.

What if I plateau at 1.0 mg and stop losing weight? Wait 8 weeks to confirm the plateau is real. If weight is stable for 8 weeks and you haven't reached your goal, escalate to 1.7 mg. If you plateau again at 1.7 mg, escalate to 2.4 mg.

Can I take more than 2.4 mg weekly? Only under the supervision of a provider experienced in obesity medicine. Doses above 2.4 mg are off-label and carry higher risks of nausea, vomiting, and pancreatitis. Most patients who plateau at 2.4 mg benefit more from adding behavioral interventions than from increasing the dose.

How long does it take to see results at a new dose? Most patients see accelerated weight loss within 2 to 4 weeks of escalating. If you don't see any change after 8 weeks at the new dose, further escalation is unlikely to help.

Is 2.4 mg of compounded semaglutide the same as Wegovy 2.4 mg? Chemically, yes. Compounded semaglutide and Wegovy both contain the same active peptide. The difference is in formulation, sterility assurance, and FDA oversight. Compounded products are not FDA-approved and have not undergone the same testing as brand-name drugs.

Do I need to reach 2.4 mg to get the full benefit of semaglutide? No. The "full benefit" is individual. If you reach your weight loss goal at 1.0 mg, there's no clinical reason to escalate further. The STEP trials measured average outcomes, but real patients have individual goals.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
4. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2022.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2022.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Obesity. 2024.
7. Tchang BG et al. High-dose semaglutide for obesity treatment: a case series. Obesity Science & Practice. 2025.
8. Svendsen B et al. Genetic determinants of semaglutide response in obesity. Nature Genetics. 2023.
9. Jensterle M et al. Metformin as an initial treatment option in obese women with polycystic ovary syndrome: a systematic review. Diabetes Care. 2021.
10. Wadden TA et al. Behavioral and dietary adherence predict weight loss outcomes in the STEP 1 trial. Obesity. 2024.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.